Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study

Medicine & Life Sciences

• Peanut Hypersensitivity 100%
• Arachis 84%
• Immune Tolerance 78%
• Immunotherapy 57%
• Placebos 44%
• Safety 38%
• Child 28%
• Psychologic Desensitization 13%
• Food 12%
• LB 30057 7%
• Immunoglobulin E 6%
• National Institute of Allergy and Infectious Diseases (U.S.) 5%
• Basophils 4%
• Population 4%
• Skin Tests 3%
• Standard of Care 3%
• Epinephrine 3%
• Intention 3%
• Hypersensitivity 2%
• Immunoglobulin G 2%
• Proteins 2%
• Research Personnel 2%
• Regression Analysis 2%
• Biomarkers 2%
• Therapeutics 1%